A. Dąbrowska-Iwanicka

发表

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up

J. Walewski, A. Borawska, J. Romejko-Jarosińska, 2022, Scientific Reports.

Primary Mediastinal Large B-cell Lymphoma

J. Walewski, A. Dabrowska-Iwanicka, A. Dąbrowska-Iwanicka, 2014, Current Hematologic Malignancy Reports.

Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R‐MIV) in patients with primary CNS lymphoma including recent COVID‐19 pandemic experience

J. Walewski, A. Borawska, J. Romejko-Jarosińska, 2023, British journal of haematology.

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma

J. Zaucha, J. Walewski, A. Pluta, 2022, British journal of haematology.

Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20

P. Parren, M. Lekka, D. Nowis, 2008, PLoS medicine.

Cardiovascular , Pulmonary and Renal Pathology Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib

D. Nowis, J. Gołąb, G. Wilczynski, 2010 .

Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation

W. Tomczak, J. Walewski, J. Romejko-Jarosińska, 2021, Leukemia & lymphoma.

First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4

J. Zaucha, W. Knopińska-Posłuszny, J. Walewski, 2019, British journal of haematology.

Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies

D. Olive, M. Słabicki, J. Gołąb, 2014, mAbs.

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

S. Montoto, N. Russell, E. Jantunen, 2019, Bone Marrow Transplantation.

Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.

K. Sułek, D. Nowis, J. Gołąb, 2010, Blood.

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience

W. Wiktor-Jedrzejczak, G. Basak, W. Knopińska-Posłuszny, 2010, Annals of Hematology.

Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.

S. Barrington, Weili Zhao, M. Jerkeman, 2023, Journal of Clinical Oncology.

Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice

J. Gołąb, G. Hoser, M. Makowski, 2002, Journal of Cancer Research and Clinical Oncology.

Relapsed or refractory primary mediastinal B-cell lymphoma: Evaluation of outcome of a minority from 125 patients treated at a single institution.

J. Walewski, J. Romejko-Jarosińska, E. Paszkiewicz-Kozik, 2014 .